PROGRAM OVERVIEW

Guided by national needs and based on the coordinated development of the Shenzhen Hong Kong Science and Technology Special Zone, we aim to cultivate high-level composite talents in "basic medicine+X" who are innovative and interdisciplinary.

Training objective: To benchmark the major strategic needs of "human health" and grasp the cutting-edge dynamics and development trends in the field of basic medical research; Integrating the characteristics of Shenzhen and Hong Kong, emphasizing interdisciplinary and practical applications, cultivating "basic medicine+X" composite medical professionals with solid basic medical theoretical knowledge and experimental skills, innovative spirit, good scientific and humanistic literacy, independent ability to engage in basic medical education, research and transformation, and international perspective.

CORE COURSES

Design and Writing of Research Projects, Advanced Experimental Techniques, Basic Medical Seminar Courses, Artificial Intelligence Medicine, Frontiers in Infection and Immunology, Frontiers in Medical Cell Biology, Advanced Physiology and Disease, Biochemistry and Molecular Biology, Molecular Pharmacology

CAREER PROSPECTS

Teaching and research positions in higher medical colleges, hospitals, research institutions, biotechnology companies.

Consultation

Email: molmed.hsc@szu.edu.cn                

专业简介

培养定位：以国家需求为导向，立足深港科技特区协同发展，培养“创新基石，学科交叉”的 “基础医学+X”高层次复合型人才。

培养目标：对标“健康中国”重大战略需求，把握基础医学研究领域前沿动态和发展趋势；融合深港特色，注重学科交叉和实践应用，培养具有扎实的基础医学理论知识和实验技能、创新精神、良好的科学人文素养、能够独立从事基础医学教育、研究与转化，具有国际视野的“重基础、精科研、能交叉、会转化”的“基础医学+X”复合型医学专业人才。

核心课程

科研项目设计与撰写、先进实验技术、基础医学seminar课程、人工智能医学、感染与免疫学前沿、医学细胞生物学前沿、高级生理学与疾病、生物化学与分子生物学、分子药理学

就业前景

高等医学院校、医院、科研机构、生物技术公司等教学与研发岗位

咨询方式

Email: molmed.hsc@szu.edu.cn

英文名

Liu Baohua

联系邮箱

Ppliew@szu.edu.cn

中文简介

北京大学学士，香港大学博士，国家杰青、优青、青年特聘专家，广东省优粤人才（A类），深圳市孔雀人才，深圳大学特聘教授，博士生导师，基础医学院院长，校学术委员会副主任（理工医），国家生化工程技术研究中心（深圳）主任，深圳市系统衰老与主动健康重点实验室主任。任亚洲衰老研究学会秘书长，中国老年医学学会基础与转化医学分会副会长，中国生物物理学会衰老生物学专业委员会副会长，中国老年学和老年医学学会老年病学分会常务委员，中国细胞生物学会衰老细胞生物学分会常务委员。主持国家自然科学基金重大项目、香港研究资助局等科研基金，从事衰老机制与干预策略研究，在Nat Med, Cell Metab, Nat Metab, Sci Adv, Nat Commun, EMBO J, Elife 等国际高水平期刊发表学术论文，获教育部自然科学二等奖[2022]、深圳市自然科学一等奖[2022]。

英文简介

Bachelor's degree from Peking University, Ph.D. from the University of Hong Kong, The National Science Fund for Distinguished Young Scholars, Excellent Young Scientists Fund, Guangdong Province Excellent Talent (Category A), Shenzhen Peacock Talent, Distinguished Professor at Shenzhen University, Ph.D. Supervisor, Dean of the School of Basic Medicine, Deputy Director of the Academic Committee of the University(Medical Science and technology), Director of the National Biochemical Engineering Technology Research Center (Shenzhen), and Director of the Shenzhen Key Laboratory of System Aging and Active Health. He has led major projects funded by The National Natural Science Foundation of China and the Hong Kong Research Grants Council, conducting research on aging mechanisms and intervention strategies. He has published academic papers in high-level international journals such as Nat Med, Cell Metab, Nat Metab, Nat Aging, Sci Adv, Nat Commun, EMBO J, and Elife, and has received the Second Prize in Natural Science from the Ministry of Education [2022] and the First Prize in Natural Science from Shenzhen [2022].

英文名

Cai Yi

联系邮箱

Caiyi0113@szu.edu.cn

中文简介

蔡毅，长聘副教授，博士生导师，深圳大学生物安全三级实验室副主任。长期从事结核感染发病机制研究，主要包括：1）结核发生发展与细胞异质性；2）细菌与宿主相互作用的机制；3）抗结核药物筛选及其作用机制；4）结核感染宿主免疫保护机制。研究相关成果发表在Journal of Clinical Investigation，Journal of Experimental Medicine，PLOS Pathogens，mBio等杂志，发明专利11项，转化1项，完成靶向宿主治疗结核病药物SASP临床III期试验。主持国家自然科学4项、深圳市学科布局项目1项、重点项目1项、深圳市医科院一般项目等。相关成果获广东省科技进步奖二等奖，深圳市自然科学二等奖。

英文简介

Dr. Yi Cai is currently an Associate Professor with Tenure in the Department of Pathogenic Biology, Shenzhen University Medical. His research interests lie in host-pathogen interactions and Tuberculosis (TB) disease progression. His primary research areas include: the relationship between cellular heterogeneity and tuberculosis development; the mechanisms of host-pathogen interactions in tuberculosis; screening and mechanisms of anti-tuberculosis drugs; host immune protection mechanisms against tuberculosis infection. His research findings have been published in journals such as Journal of Clinical Investigation, Journal of Experimental Medicine, PLOS Pathogens, and mBio. He holds 11 invention patents, with one successfully commercialized, and has completed a phase III clinical trial for the host-targeted tuberculosis drug SASP. He has led four projects funded by the National Natural Science Foundation of China and several grants from Shenzhen. His work has earned him the Second Prize of the Guangdong Provincial Science and Technology Progress Award and the Second Prize of the Shenzhen Natural Science Award.

英文名

Xue Liu

联系邮箱

xueliu@szu.edu.cn

中文简介

刘雪, 深圳大学医学部副教授，深圳市海外高层次人才，广东省特支计划青年拔尖人才获得者。2021年8月入职深圳大学医学部，组建人类病原性细菌研究团队（http://xliugroup.com/）。近年发表SCI论文20余篇，其中第一作者（含共同一作）论文10篇，包括Cell Host & Microbe, Molecular Cell, Nature Protocols, Molecular Systems Biology (封面文章）等国际知名高水平期刊。首次鉴定了LafB可为广谱的链球菌菌的疫苗靶点，并获国际专利1项。

“克菌治病”课题组目前研究方向包括以下三个方面：

1） 重要人类病原细菌的致病机理。

2） 肠道非模式细菌的高效遗传筛选平台开发。

3)  采用时空组学探究细菌感染关键病灶的发病机制。

英文简介

Liu Xue is an associate professor at the Medical School of Shenzhen University, a high-level overseas talent in Shenzhen, and a recipient of the Guangdong Province Special Support Program for Young Talents. In August 2021, she joined the Medical School of Shenzhen University and established the Human Pathogenic Bacteria Research Team (http://xliugroup.com/). In recent years, she has published more than 20 SCI papers, including 9 as the first author or co-first author, in internationally renowned high-level journals such as Cell Host & Microbe, Molecular Cell, Nature Protocols, and Molecular Systems Biology (cover article). She identified LafB as a target for pneumococcal vaccine develop with wide-range protection against strains with different serotypes.

Our "Fighting Bacterial Diseases" research group is currently focused on three main areas:

1) The pathogenic mechanisms of important bacterial human pathogens.

2) The development of efficient genetic screening platforms for non-model bacteria in the gut.

3) Using spatial and temporal omics to explore the pathogenesis of key lesions in bacterial infections.

英文名

Huiqiang Lou

联系邮箱

lou@szu.edu.cn

中文简介

 楼慧强，博士，深圳大学医学部特聘教授。1997年本科毕业于北京大学生命科学学院，2004年博士毕业于中国科学院微生物研究所。2004-2009年在加州理工学院先后从事博士后、CIRM fellow 工作，2009-2020年中国农业大学生物学院教授、博导，历任微生物学与免疫学系系主任、科研副院长、农业生物技术国家重点实验室副主任。担任中国微生物学会理事、《微生物学报》、《mLife》、《Engineering Microbiology》编委。

主要从事糖代谢与DNA复制研究。主持国家自然科学基金重点项目1项、面上项目4项、参与国家“重点研发”重大专项子课题1项。近5年以通讯作者在Gen & Dev、EMBO Rep、CMLS、Cell Rep、PLoS Genet等杂志发表论文30余篇；获得国家发明专利2项，申请PCT专利2项。

英文简介

The Lou Group is devoted to uncover the potential crosstalk between metabolic dysregulation and genome instability, the two major resources which are considered to underlie cancer initiation. We apply multidisciplinary approaches such as genetics, biochemistry, cell biology, quantitative biology and synthetic biology to investigate DNA replication, co-replication events and whether/how sugar metabolism affects DNA replication/genome integrity. Our recent high-impact publications include Genes & Dev, EMBOJ, Cell Rep, EMBO Rep, CMLS, PLoS Genet.  

英文名

Sisi Li

联系邮箱

liss@szu.edu.cn

中文简介

2013年获复旦大学博士学位，随后加入纽约纪念斯隆凯特琳癌症中心（MSKCC）从事博士后研究。2016-2021年任南方科技大学生物系研究副教授，2021年加入深圳大学卡尔森国际肿瘤中心任特聘教授。 国家级青年人才，深圳市杰出青年人才。

李思思博士近年来专注RNA转录后调控的机制研究，通过多种生物学研究手段，建立从RNA的化学结构，到RNA与相关蛋白质的调控机制与生理功能，最后到RNA药物开发的联合体系。近五年来以第一或通讯（含共同）作者身份在Science、 Nat Commun和 PNAS等学术期刊上发表学术论文十余篇，部分研究成果获同期专评，以及学术媒体Faculty Opinion的推荐，并担任多个知名期刊的审稿人。

英文简介

Dr. Li Sisi obtained her Ph.D. degree from Fudan University in 2013, and joined the Memorial Sloan Kettering Cancer Center in New York for postdoctoral research. From 2016 to 2021, she was an Associate Professor at the Department of Biology at Southern University of Science and Technology, and in 2021, she joined the Carlson International Cancer Center at Shenzhen University as professor. She was awarded the National Science Foundation for Outstanding Young Scholars and Outstanding Young Talents of Shenzhen.

In recent years, Dr. Li has focused on the mechanisms of RNA post-transcriptional regulation. Using various biological research methods, she has established a joint system from the chemical structure of RNA to the regulation mechanism and physiological function of RNA with relevant proteins, and finally to RNA drug development. In the past five years, she has published over ten academic papers as the first or corresponding author in high-profile journals such as Science, Nature Communications, and PNAS. Some of her research achievements have received specialized reviews and recommendations from academic media such as Faculty Opinion, and she has also served as a reviewer for several well-known journals.

英文名

Yin Peng

联系邮箱

ypeng@szu.edu.cn

中文简介

2010年毕业于Loyola University Chicago获生物医学博士学位。现任深圳大学医学部病理学系副教授。主要研究方向是胃肠道肿瘤中的非编码RNA作用机制及其相关信号通路，发表SCI一作和通讯作者论文20篇，包括 Oncogene，Molecular Cancer，Cancer Letters等。主持国家自然科学基金2项、广东省自然科学基金2项及广东省医学科学基金，深圳市基础研究，深圳高层次人才基金，深圳大学启动基金等多个项目，总经费超过500万。美国肿瘤学会AACR会员。深圳市孔雀C类人才。

英文简介

Dr. Yin Peng received the PhD degree in Molecular and Cellular Biochemistry from Loyola University Chicago in 2010. She is currently an associate professor in Department of Pathology at Shenzhen University, China. Her long-standing research interests lie in elucidating the molecular mechanisms of cell signaling transduction pathway underlying tumorigenesis. Her lab is actively exploring how oncogenic circRNAs regulate critical signaling transduction pathways, such as the Wnt/β -catenin pathway and NF-κB signaling pathway to promote cell survival, proliferation and migration in cancer cells. She has published over 20 first author/corresponding author papers in professional, peer-reviewed journals including Oncogene, Molecular Cancer, Cancer Letters. She is an AACR member and Shenzhen Peacock Talent C.

英文名

Yong-Xian Cheng

联系邮箱

yxcheng@szu.edu.cn

中文简介

程永现，深圳大学特聘教授，药学院院长，长期从事中药科学原理研究与新药转化工作，主要是在中医药理论和仿生学启发下，运用“衷中参西”的方法围绕重大疾病和“未病”开展中药有效成分的发现与作用机制、中药配伍原理指导下的结构优化以及中药有效成分挖掘的方法学研究。迄今已在Organic letters, Natural Product Reports, Acta Pharmaceutica Sinica B, British Journal of Pharmacology, Medicinal Research Reviews等国内外核心期刊发表学术论文150余篇。近年来主持或完成国家杰出青年科学基金、国家自然科学基金委员会-云南省联合基金重点项目等多项基金。其带领的团队以“回归临床”为终极目标，借鉴中医象思维模式，注重方法和策略开发，试图采用化学生物学、医工结合等手段，以中药小分子化合物或中医治疗方法为工具探索五脏之间的生克制化规律、天然分子的生化机制等，借此发现新的病理机制或有效药物，也阐释中医药疗效的科学内涵。目前研究方向主要有：调控重大疾病及未病的中医药智慧设计、特色中药药效物质挖掘及天然可及性研究；具有成药前景中药成分的有机全合成及工艺优化研究；中药有效或毒性成分的分子设计、结构修饰与优化；中药有效成分的作用机制及器官间生克制化的规律研究；中药有效成分为探针的疾病新靶标发现与确证研究；中药有效成分的生物合成途径解析及合成生物学研究。

英文简介

Yongxian Cheng is a distinguished professor at Shenzhen University and the Dean of the School of Pharmacy. He has long been engaged in research on the scientific principles of traditional Chinese medicine (TCM) and the translation of new drugs. His work primarily focuses on the discovery and mechanism of action of effective components in TCM, structural optimization guided by TCM compatibility principles, and methodological research on the extraction of effective components, all inspired by TCM theory and biomimicry. To date, he has published over 150 academic papers in core journals such as Organic letters, Natural Product Reports, Acta Pharmaceutica Sinica B, British Journal of Pharmacology, Medicinal Research Reviews.

In recent years, he has led or completed several projects funded by the National Science Fund for Distinguished Young Scholars and key projects under the National Natural Science Foundation of China and Yunnan Province Joint Fund. His team aims to "return to clinical practice" as the ultimate goal, utilizing TCM symbolic thinking and emphasizing method and strategy development. They attempt to use chemical biology and the integration of medicine and engineering to explore the interactions between the five organs and the biochemical mechanisms of natural molecules, employing TCM small molecules or therapeutic methods as tools to discover new pathological mechanisms or effective drugs, and to elucidate the scientific connotations of TCM efficacy.

Current research directions include: intelligent design of TCM for the regulation of major diseases and preventive medicine; exploration of effective substances in characteristic TCM and studies on natural accessibility; organic total synthesis and process optimization of TCM components with drug potential; molecular design, structural modification, and optimization of effective or toxic components in TCM; studies on the mechanisms of action of effective components and the rules of interactions between organs; discovery and verification of new disease targets using effective components in TCM as probes; and analysis of biosynthetic pathways of effective components and research in synthetic biology.

英文名

Liu Qi

联系邮箱

Liu_qi@szu.edu.cn

中文简介

德国海德堡大学获得放射治疗学博士博士，深圳大学医学部卡尔森国际肿瘤中心副教授。先后在美国哈佛大学医学院作为博士后研究员、加州大学旧金山分校担任项目科学家开展放射肿瘤学研究。刘琦博士长期从事放射医学与癌症精准医疗的临床前研究，作为课题负责人带领团队研究了癌症的DNA损伤反应、肿瘤放疗免疫学影响、药物靶点相关机制、硼中子俘获疗法及放射性核素药物等课题。研究成果包括建立了世界首个放射增敏靶向药物筛选平台，攻克了人乳头瘤病毒影响肿瘤放射敏感性机制的难题，揭示了质子射线造成的DNA损伤特点及其修复机制等。现已发表SCI论文50余篇，多项重要研究成果以第一作者发表在Science Translational Medicine、Clinical Cancer Research、Oncogene等国际著名学术期刊上；担任多个SCI学术期刊的编委及审稿专家；是国际放射研究学会、美国癌症研究学会、中华放射肿瘤专业委员会、中国核学会放射性药物分会等学术组织成员。

英文简介

Dr. Liu Qi received his Ph.D. in Radiation Therapy and Oncology from Heidelberg University in Germany, currently serve as an associate professor at the International Cancer Center, School of Medicine, Shenzhen University. He was a postdoctoral research fellow at Harvard Medical School and an associate scientist at the University of California, San Francisco. Dr. Liu is an enthusiastic researcher in precision cancer medicine. In the past decade, he has studied mechanisms of DNA damage response, molecular targeted radiation therapy, boron neutron capture therapy, and radiopharmaceuticals for cancer treatment. His pioneer work has given rise to the world's first high-throughput screening platform for identifying molecular targeted drugs with radiosensitizing properties, discovery of DNA damage features caused by proton beams and their repair mechanisms, revelation about HPV induced radiation response in head and neck cancer, etc. Dr. Liu has published over 50 academic articles in the renowned journals such as Science Translational Medicine, Clinical Cancer Research, etc. Dr. Liu serves as an editorial board member and reviewer for a number of SCI journals, and members in Radiation Research Society, American Association for Cancer Research, Chinese Society of Radiation Oncology, etc.

英文名

Bin Peng

联系邮箱

binpeng@szu.edu.cn

中文简介

彭斌，副教授，博士生导师，特聘研究员，深圳市高层次人才。长期致力于基因组不稳定性与人类疾病（如肿瘤、先天性小头畸形）方面的研究，侧重于翻译后修饰调控DNA损伤/DNA复制胁迫应答的分子机制，并聚焦靶向基因组稳定性的抗癌先导物筛选及分子机制阐明。以一作或通讯作者在国际主流杂志PNAS、NAR、eLife、iScience、Cell & Bioscience和EJMC等发表SCI 论文20余篇。主持国家重点研发计划子课题，国家自然科学基金面上项目、青年项目，广东省自然科学基金青年提升、面上项目，深圳市科技计划基础研究项目等7个纵向科研基金。参与国家自然科学基金重大项目、重点项目及国际合作等5项。

英文简介

Dr. Peng Bin, an associate professor with tenure in the Department of Cell Biology, Shenzhen University Medical School. He focuses on the molecular mechanisms of the DNA damage response and human diseases (such as cancer, primary microcephaly), especially addressing how the posttranslational modifications (PTMs) regulate the DNA damage response. He has published more than 20 papers in PNAS, NAR, eLife, iScience, Cell & Bioscience and EJMC. (1) The molecular mechanism of DNA damage response and tumorigenesis. (2) Elucidation of the pathogenic mechanistic link between genome instability and primary microcephaly. (3) Development of anti-cancer lead compounds targeting genome stability, screening and characterizing anti-cancer lead compounds such as chalcone and quinazoline derivatives, and revealing their anti-cancer mechanism.

英文名

SHU, Xingsheng

联系邮箱

shu@szu.edu.cn

中文简介

舒兴盛，博士，副教授，博士生导师，深圳大学“荔园优青”，深圳市海外高层次人才，本科毕业于北京大学生命科学学院，博士毕业于香港中文大学医学院，现任深圳大学医学部基础医学院副教授、特聘研究员。舒兴盛副教授长期致力于肿瘤转录和表观遗传调控异常的机制及相关的转化治疗研究，以通讯或第一作者在PNAS，Cancer Research，Oncogene和Journal of Pathology等国际权威学术期刊发表论文三十余篇，被引用1500余次，H-index为21，以第一发明人获得两项中国发明专利授权，主持包括国自然面上项目在内的多项国家和省市级项目，担任国际表观遗传协会理事。指导研究生获深圳大学“百篇优秀硕士学位论文”和深圳大学优秀毕业生等荣誉。更多研究情况请参看链接：https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/。

英文简介

Dr. Xing-sheng Shu received his B.S. degree from the School of Life Sciences, Peking University and his Ph.D. degree from the Department of Clinical Oncology, The Chinese University of Hong Kong. He is currently an Associate Professor at the School of Medicine, Shenzhen University. Dr. Shu has been working on abnormal epigenetic and transcriptional regulation in cancer and related translational research for cancer therapy. He has published more than 30 SCI papers with more than 1500 citations and an H-index of 20, including more than 10 papers in PNAS, Oncogene, Cancer Resarch, Journal of Pathology and other high impact journals in recent 5 years as corresponding or first author. He also holds two invention patents, and completed many national and provincial research projects. Graduate students supervised by Dr. Shu were awarded by “One Hundred Outstanding Master's Degree Theses of Shenzhen University” and “Outstanding Graduate of Shenzhen University”. For more information about his research, please refer to the link: https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/.

英文名

Lei Wang

联系邮箱

lei.wang@szu.edu.cn

中文简介

香港科技大学本科与硕士学位，美国加州大学河滨分校博士学位，美国希望之城(City of Hope)国家医学中心博士后。研究方向长期聚焦肿瘤免疫学, 与临床医生紧密合作，运用单细胞多组学、空间多组学和高参数流式细胞术等技术，结合生物信息学，探究肿瘤发生发展对患者全身性免疫系统的影响作用，揭示免疫疗效机理机制，并寻找免疫治疗标志物。近年来以第一作者在Nature Immunology等国际刊物共发表学术论文10余篇，现主持国自然重大研究计划培育项目等科研项目。

英文简介

The focus of my research is on exploring how immunotherapy impacts the dynamic of immune responses in patients with solid tumors, with the goal of understanding the immunoregulatory mechanisms of host systemic immunity and developing novel prognostic/predictive biomarkers. We utilize state-of-the-art technologies – such as single-cell multiomics, quantitative spatial image analysis, high-parameter flow cytometry and advance bioinformatics – to dissect the complex interplay between immune cells and cancer cells within tumor microenvironment and host immune macroenvironment including tumor-draining lymph nodes and peripheral blood.

英文名

XU, Xingzhi

联系邮箱

Xingzhi.Xu@szu.edu.cn

中文简介

深圳大学特聘教授、医学部执行主任，国际先进材料协会（IAAM）会士，《Genome Instability & Disease》常务主编、中国细胞生物学学会细胞信号转导分会副会长（2015-2023）。长期致力于DNA损伤应答、DNA复制及复制应激、基因组稳定性维持的研究，并开发靶向基因组稳定性的抗癌先导化合物。在国际主流杂志发表SCI论文100余篇；主编《肿瘤生物学导论》（科学出版社，2014）。2011年创建DNA损伤应答北京市重点实验室并任主任（2011-2017）；2010年创办并连续主办DNA损伤应答与人类疾病国际研讨会（isDDRHD）年会系列并成为有国际影响力的品牌会议，是中国DNA修复领域的核心召集人。

英文简介

Distinguished Professor of Shenzhen University,Executive Dean of School of Medicine, Fellow of the International Association for Advanced Materials (IAAM), Deputy Editor-in-chief of Genome Instability & Disease, Vice President of Chinese Society for Cell Signal Transduction, CSCB (2015-2023). He has long been devoted to the research of DNA damage response, DNA replication and replication stress response, and maintenance of genome stability, and has developed anticancer lead compounds targeting genome homeostasis. He has published more than 100 SCI papers in international mainstream journals; edited "Principles of Cancer Biology" (Science Press, 2014). In 2011, he founded the Beijing Key Laboratory of DNA Damage Response and served as the director (2011-2017); in 2010, he founded and successively hosted the annual conference series of the international symposium on DNA Damage Response and Human Diseases (isDDRHD), which has become an internationally influential brand conference. Therefore, he becomes the core convener in the field of DNA repair in China.

英文名

YING YING

联系邮箱

yingying@szu.edu.cn

中文简介

应颖，教授，博士生导师，深圳市海外高层次B类人才，医学部基础医学院副院长兼生理学系主任。长期从事表观遗传变异所致的转录调控异常参与代谢性、神经退行性疾病及肿瘤的发生发展的分子机制及干预研究。主持国家自然科学基金4项及省、市级项目多项。以第一或通讯作者（含共同）在Molecular Neurodegeneration, PNAS, Cancer Research, Oncogene, Journal of Pathology等国际著名期刊上发表论文30余篇。

英文简介

Prof. Ying Ying (MD, PhD) is Vice Dean of the Department of Physiology at Shenzhen University Health Science Center. Her research focuses on epigenetic dysregulation in contribution to the pathogenesis of metabolic and neurodegenerative diseases as well as colorectal cancer. She has presided over the completion of a number of research projects including the National Natural Science Foundation of China. As the corresponding author or first author, she has published over 30 research articles in top journals (i.e.,Molecular Neurodegeneration, PNAS, Cancer Research, Oncogene, Journal of Pathology, etc.).

英文名

Jingzhu Zhang

联系邮箱

zjz@szu.edu.cn

中文简介

张景筑，博士，深圳大学医学部百人计划助理教授，特聘研究员，独立PI，博士生导师。本科毕业于美国威斯康星大学麦迪逊分校，博士毕业于圣路易斯华盛顿大学，后于德克萨斯大学西南医学中心的Sean Morrison教授（美国科学院与医学院院士，HHMI研究员）课题组从事博士后研究，并于2024年3月入职深圳大学。张景筑博士长期研究骨骼与骨髓微环境，累计发表SCI论文10篇，其中以第一作者发表论文4篇，包括PNAS（两篇）、Journal of Clinical Investigation与Journal of Bone and Mineral Research等国际高水平期刊。

研究方向：骨髓微环境、骨骼干细胞、骨再生、骨衰老、骨损伤修复

英文简介

Jingzhu Zhang, Ph.D., is a Hundred-Talents assistant professor at the Medical School of Shenzhen University, principal investigator and supervisor of Ph.D./master students. He received his B.S. degree from the University of Wisconsin-Medicine in the U.S.A., and Ph.D. degree from the Washington University in St. Louis, and completed his postdoctoral fellowship in the University of Texas Southwestern Medical Center supervised by Dr. Sean Morrison (member of National Academy of Science and National Academy of Medicine of the U.S.A., and investigator of Howard Hughes Medical Institute). In March, 2024, Dr. Zhang joined Shenzhen University. Dr. Zhang has been focusing on the research of bone and bone marrow microenvironment, and has published 10 SCI papers. As first-author, he published in internationally renowned high-level journals including PNAS (2 papers), Journal of Clinical Investigation and Journal of Bone and Mineral Research.

Research interest: Bone marrow microenvironment, skeletal stem cell, bone regeneration, bone aging, bone repair

英文名

Suping Zhang

联系邮箱

s9zhang@szu.edu.cn

中文简介

2007年获清华大学博士学位，随后加入加州大学圣地亚哥分校从事博士后科学研究，2012年留校任教。2015年被深圳大学聘为副教授;2023年晋升为教授，博士生导师。张博士长期致力于肿瘤生物学及免疫靶向治疗新药的研究，利用细胞生物学、生物化学、分子生物学、免疫学、生物信息学等多学科分析方法,研究肿瘤发生、发展、转移及复发的机制及寻找新的治疗靶标，据此开发靶向消除肿瘤细胞或改变其微环境的免疫治疗新药有望治愈癌症。到目前为止，张博士主要开发的进入临床试验阶段的用于免疫治疗的一类新药有两个;发表高水平学术论文27篇，其中第一作者及通讯作者论文16篇(含3篇PNAS)，引用次数超过2000。拥有国内外发明专利9项，其中一项已经商业化。承担国家重点研发计划、国家自然科学基金面上项目、深圳市海外创新孔雀团队等项目共11项。2011年获第53届美国血液学年会摘要成就奖。

英文简介

Dr. Zhang obtained her PhD degree from Tsinghua University in 2007, and then joined the University of California, San Diego for postdoctoral scientific research, and stayed in the university as a faculty member in 2012. She was appointed as Associate Professor by Shenzhen University in 2015; and was promoted to Professor in 2023. Dr Zhang’s research interests lie in: Using multidisciplinary approach of molecule cell biology, cell biology, biochemistry, immunology and bioinformatics to investigate the molecular mechanism underlying tumor initiation, metastasis and relapse, and develop novel small compounds and immunological therapeutics for patients with cancer. So far, Dr. Zhang has developed two novel anti-cancer drugs which are under clinical investigation currently.  She had co-authored 27 publications which include 3 PNAS and one publication on Oncogene as first or corresponding authors. She had 9 patents and one of them already was commercialized. She has been funded by National Key R&D plan, National Natural Science Foundation of China (NSFC), Shenzhen Peacock Innovation Team Grant and so on. She had been awarded “Excellent Abstract Achievement” by American Society of Hematology (ASH) at 2011.